Details for Patent: 10,098,892

Which drugs does patent 10,098,892 protect, and when does it expire?

Patent 10,098,892 protects BELSOMRA and is included in one NDA.

This patent has eighteen patent family members in ten countries.

Summary for Patent: 10,098,892

Title:	Solid dosage formulations of an orexin receptor antagonist
Abstract:	The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer. A concentration-enhancing polymer is water soluble or readily disperse in water, so that when the polymer is placed in water or an aqueous environment (e.g. fluids in the gastrointestinal (GI) tract or simulated GI fluids), the solubility and/or bioavailability of suvorexant is increased over the solubility or bioavailability in the absence of the polymer.
Inventor(s):	Harmon; Paul A. (Audubon, PA), Variankaval; Narayan (Plainsboro, NJ)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	14/404,147
Patent Claim Types: see list of patent claims	Composition; Process;

Drugs Protected by US Patent 10,098,892

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No			Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-002	Aug 13, 2014		RX	Yes	No			Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No			Y
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-004	Aug 13, 2014		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 10,098,892

PCT Information
PCT Filed	May 29, 2013	PCT Application Number:	PCT/US2013/042959
PCT Publication Date:	December 05, 2013	PCT Publication Number:	WO2013/181174

International Family Members for US Patent 10,098,892

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013267613
Australia	2018201279
Brazil	112014025041
Canada	2795550